These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Technology evaluation: NeuroVax, Immune Response Corp.
    Author: Darlington CL.
    Journal: Curr Opin Mol Ther; 2005 Dec; 7(6):598-603. PubMed ID: 16370383.
    Abstract:
    The Immune Response Corp is developing NeuroVax, a combination vaccine of three T-cell receptor peptides (BV5S2, BV6S5 and BV13S1) in incomplete Freund's adjuvant, as a potential treatment for multiple sclerosis. The vaccine is currently undergoing phase II clinical trials.
    [Abstract] [Full Text] [Related] [New Search]